{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.4","upperLimit":"16.6","value":"10.2"},{"comment":"NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.","groupId":"OG001","lowerLimit":"8.3","upperLimit":"NA","value":"19.2"},{"groupId":"OG002","lowerLimit":"5.7","upperLimit":"16.7","value":"11.4"},{"comment":"NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.","groupId":"OG003","lowerLimit":"7.2","upperLimit":"NA","value":"9.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"The PFS was defined as the time from the start of study drug until the first objective PD as defined by RECIST v1.1 or death, whichever came first. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters. The appearance of 1 or more new lesions was also considered progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with NET of lung origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.","id":"OG000","title":"Cohort A (NET, Lung)"},{"description":"Patients with NET of small bowel origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.","id":"OG001","title":"Cohort B (NET, Small Bowel)"},{"description":"Patients with NET of non-small bowel, non-pancreas, and non-lung origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.","id":"OG002","title":"Cohort C (NET, Other)"},{"description":"Patients with NET of any origin received a single dose of drug cocktail (midazolam 2.5 mg, fexofenadine 30 mg and rosuvastatin 10 mg) on Day -2 followed by surufatinib 300 mg orally QD from C1D1 to C1D14. On C1D15, a single dose of surufatinib 300 mg and a single dose of drug cocktail as above was administered. Patients received surufatinib 300 mg orally QD from C1D16 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.","id":"OG003","title":"Cohort D (NET, Any)"}],"paramType":"MEDIAN","populationDescription":"The safety analysis set included all patients who received at least 1 dose of surufatinib.","reportingStatus":"POSTED","timeFrame":"RECIST assessments performed at screening (within 28 days before start of study drug), every 8 weeks for the first 24 weeks from C1D1, then every 12 weeks thereafter until the occurrence of disease progression, up to approximately 36 months","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}